Trbovich

Trbovich said Penn's business interests have been an issue within the union for some time.

The Penn Effect 2008

"There have been some long-standing concerns about Mark Penn, who runs an anti-union business inside his firm," Trbovich said.

The Penn Effect 2008

But Trbovich did say that the union's overall membership believes "there's a moral component with Colombia because of the assassination of a number of trade unionists … We are deeply and fundamentally opposed to a Colombian trade agreement, because it would represent a surrender to our basic commitment to human rights."

The Penn Effect 2008

Should GlaxoSmithKline and other companies working on a bird flu vaccine hit significant milestones this year, said Trbovich, "Novavax's shares are likely in for a significant correction to the downside."

Novavax Has 'Significant' Sell-Off Potential 2006

"The revenue disappointment in this category despite better than expected retail sales leads us to believe that the company bled down inventory in the channel, possibly in anticipation of an upcoming launch of a new version of Dynacin," Trbovich wrote in a research report.

Medicis Shares Could Get Boost From Near-Term Catalysts 2006

Trbovich said Noven's first-quarter revenues of $10.2 million came in lower than consensus estimates of $11.7 million, as did product revenues of $4.8 million from sales at Novogyne, which missed Morgan Stanley's estimate of $6.6 million.

Noven's Q1 Miss 2006

The company added that the increase in international sales, which brought in $1.4 million more than the $3.9 million Trbovich had forecasted, was also due to ordering patterns.

Noven's Q1 Miss 2006

Should GlaxoSmithKline and other companies working on a bird flu vaccine hit significant milestones this year, said Trbovich, "Novavax's shares are likely in for a significant correction to the downside."

Novavax Has 'Significant' Sell-Off Potential 2006

"The Reloxin agreement with Ipsen gives us continued confidence that Medicis will deliver growth from its pipeline," said Trbovich.

Medicis Shares Could Get Boost From Near-Term Catalysts 2006

Trbovich said Medicis' recently-announced licensing deal with French drug firm Ipsen for cosmetic drug Reloxin, a potential competitor to Botox, could send shares higher if the late-stage drug is approved by health regulators in May.

Medicis Shares Could Get Boost From Near-Term Catalysts 2006